Name: 글로벌 시장 동향
SKU: PH6761
Availability: InStock

보고서 요약(국문)

개요
전 세계 전이성 직장암 시장은 2022년 34억 달러 규모에 달했으며, 2023년부터 2030년까지 연평균 4.6%의 성장률을 보이며 2030년에는 48억 달러에 이를 것으로 예상됩니다. 전이성 직장암 시장의 성장은 발병률 및 유병률 증가, 연구 개발 활동 확대, 정부 정책 추진 등의 요인에 의해 주도되고 있습니다.
유전적 변이, 종양 미세환경과의 상호작용, 기타 외부 요인들은 모두 직장암 전이에 영향을 미칩니다. 전이성 직장암(mCRC) 치료에는 전신 항암화학요법, 표적 치료, 면역요법의 세 가지 치료법이 사용될 수 있습니다.

시장 동향
전이성 직장암 치료에 대한 FDA 승인 증가가 전 세계 전이성 직장암 시장 성장을 견인하고 있습니다.
2023년 1월, 투카티닙(Tukysa, Seagen Inc.)과 트라스투주맙은 플루오로피리미딘, 옥살리플라틴, 이리노테칸 기반 화학요법 후 진행된 RAS 야생형 HER2 양성 전이성 또는 절제 불가능 직장암 치료제로 미국 식품의약국(FDA)의 신속 승인을 받았습니다. MOUNTAINEER(NCT03043313)라는 공개 라벨 다기관 임상 시험에서 84명의 환자를 대상으로 효과를 평가했습니다.
환자들은 과거에 HER2 양성, RAS 야생형, 절제 불가능 또는 전이성 직장암으로 플루오로피리미딘, 옥살리플라틴, 이리노테칸 및 항혈관내피성장인자(VEGF) 단클론항체(mAb) 치료를 받은 경험이 있습니다. 항-프로그램 세포 사멸 단백질-1 단클론항체 치료가 필요한 환자들은 또한 불일치 복구(dMMR) 단백질이 결핍되었거나 미세위성 불안정성(MSI-H)이 높은 종양을 가지고 있었습니다.
연구 활동 증가가 전 세계 전이성 직장암 시장 성장을 견인하고 있습니다.
2023년 5월, 다케다와 허치메드(중국)는 FDA가 이미 치료를 받은 성인 전이성 직장암(CRC) 환자 치료를 위한 고효능 및 선택적 VEGFR-1, -2, -3 억제제인 프루퀸티닙의 신약 허가 신청(NDA)을 우선 심사 대상으로 승인했다고 발표했습니다.
승인될 경우, 프루퀸티닙은 이미 치료를 받은 전이성 직장암 환자를 대상으로 미국에서 승인된 최초이자 유일한 고선택성 VEGF 수용체 억제제가 될 것입니다. FDA는 이 NDA에 대한 처방약 사용자 수수료법(PDUFA) 목표일을 2023년 11월 30일로 설정했습니다.

전이성 직장암 치료와 관련된 부작용이 전 세계 전이성 직장암 시장 성장을 저해하고 있습니다.
전이성 직장암 치료와 관련된 부작용은 시장 성장을 억제하는 요인입니다. 암세포는 항암화학요법의 표적이 되는 빠르게 분열하는 세포 중 하나입니다. 이러한 항암화학요법은 건강한 세포에도 영향을 미쳐 여러 가지 부작용을 초래할 수 있습니다. 메스꺼움과 구토, 피로, 탈모, 설사 또는 변비, 골수 억제(혈구 수 감소), 구내염, 신경병증(신경 손상)은 전이성 직장암 치료에 사용되는 항암화학요법의 대표적인 부작용입니다.
표적 치료는 암 발생에 관여하는 특정 화학 물질을 표적으로 합니다. 전이성 직장암(mCRC)에 대한 표적 치료는 피부 반응(발진, 건조), 고혈압, 위장 문제(설사, 메스꺼움), 피로, 간 효소 이상, 출혈 또는 혈전 위험 증가와 같은 부작용을 흔히 유발합니다.

이 보고서에 대한 자세한 내용은 샘플을 요청하십시오.
세그먼트 분석
전 세계 전이성 직장암 시장은 치료법, 약물 종류, 최종 사용자 및 지역별로 세분화됩니다.
화학요법 부문은 예측 기간 동안 시장에서 지배적인 위치를 차지할 것으로 예상됩니다.
화학요법 부문은 2022년 전이성 직장암 시장에서 약 41.3%의 점유율을 차지하며 가장 높은 시장 점유율을 기록했습니다. 2023년 국제 분자 과학 저널(International Journal of Molecular Sciences)에 발표된 논문에 따르면, 전이성 직장암의 경우 세포독성 화학요법이 여전히 가장 많이 사용되는 치료법입니다. 병용 요법의 기본은 주로 플루오로피리미딘 계열 약물입니다.

전이성 직장암(mCRC)의 1차 치료는 FOLFOX(플루오로우라실, 류코보린, 옥살리플라틴), FOLFIRI(플루오로우라실, 류코보린, 이리노테칸), 또는 FOLFOXIRI(플루오로우라실, 류코보린, 옥살리플라틴, 이리노테칸)와 같은 화학요법을 단독 또는 병용하여 시행합니다.
지리적 시장 점유율
북미, 전 세계 전이성 직장암 시장에서 지배적인 위치 차지
북미는 2023년 전체 시장 점유율의 약 39.6%를 차지할 것으로 추정됩니다. 2022년 9월, 기존 치료법이 더 이상 효과적이지 않은 전이성 직장암 환자를 위한 새로운 2상 임상시험이 콜로라도 대학교 암센터의 로버트 렌츠 박사 주도로 시작되어 희망을 제시하고 있습니다. 미국에서 직장암은 남녀 모두에서 세 번째로 흔하고 세 번째로 치명적인 암입니다. 더욱이, 화학요법과 생물학적 요법이 환자에게 더 이상 효과가 없을 경우, 사용 가능한 치료 대안이 많지 않습니다.
이 문제는 대장암 환자의 약 95%가 이미 승인된 면역 치료제에 반응하지 않는다는 사실로 인해 더욱 악화됩니다. 이러한 환자들의 수명을 연장하기 위해서는 항종양 면역 반응을 유도할 수 있는 방법을 찾아야 합니다.
경쟁 환경
시장의 주요 글로벌 업체로는 Amgen, EMD Serono, Eli Lilly, Genentech, Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Sanofi, Suzhou Zelgen Biopharmaceuticals, Taiho Oncology 등이 있습니다.
COVID-19 영향 분석
러시아-우크라이나 분쟁 분석
러시아-우크라이나 전쟁은 지정학적 불안정과 경제적 불확실성으로 인해 의료 시설 부족을 초래하여 전이성 대장암 시장에 영향을 미칠 수 있습니다. 암 치료법의 발전을 위해서는 임상 시험이 필수적입니다. 의견 불일치로 인해 전이성 대장암에 대한 새로운 치료법 개발이 지연되고, 신규 환자 등록이 늦어지며, 적절한 데이터 수집이 어려워질 수 있습니다. 분쟁 발생 시 의료 인프라와 시설이 파괴되거나 과부하될 수 있으며, 이로 인해 전이성 대장암 환자에게 필요한 보조 치료와 전문적인 암 치료를 제공하는 것이 더욱 어려워질 수 있습니다.
인공지능 분석:
인공지능(AI)은 데이터 분석의 다양한 측면을 개선하기 위해 전이성 대장암 시장에서 점점 더 많이 활용되고 있습니다. 전이성 대장암에 대한 유망한 치료 후보 물질과 분자 표적을 찾기 위해 AI는 복잡한 생물학적 및 유전체 데이터를 분석하는 신약 개발에 활용됩니다. 특정 종양 변이와의 잠재적인 약물 상호작용을 예측함으로써 신약 개발 과정을 가속화할 수 있습니다.

치료 유형별
• 화학요법
• 표적 치료
• 면역요법
• 단독요법 및 병용요법
• 기타
약물 계열별
• 항EGFR(상피세포 성장인자 수용체) 억제제
• 항VEGF(혈관내피세포 성장인자) 치료제
• 항HER2(인간 상피세포 성장인자 수용체 2) 치료제
• 면역 체크포인트 억제제
• 기타
최종 사용자별
• 병원
• 암센터
• 외래 수술 센터
• 기타
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
주요 동향
• 2023년 8월, 타이호 온콜로지(Taiho Oncology, Inc.)와 타이호 제약(Taiho Pharmaceutical Co., Ltd.)은 미국 식품의약국(FDA)이 플루오로피리미딘, 옥살리플라틴, 이리노테칸 기반 화학요법, 항 VEGF 생물학적 요법, 그리고 RAS 야생형인 경우 항 EGFR 요법으로 이전에 치료받은 전이성 직장암 성인 환자 치료를 위해 론서프(LONSURF, 트라이플루리딘/티피라실)를 단독 요법 또는 베바시주맙과의 병용 요법으로 승인했다고 발표했습니다.
보고서 구매 이유

• 치료법, 약물 종류, 최종 사용자 및 지역별 전 세계 전이성 직장암 시장 세분화를 시각화하고 주요 상업적 자산과 기업을 파악하기 위해

• 시장 동향 및 공동 개발 분석을 통해 상업적 기회를 식별하기 위해

• 모든 세그먼트를 포함한 전이성 직장암 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트 제공

보고서 구매 이유 • PDF 보고서는 철저한 질적 인터뷰와 심층 연구를 바탕으로 한 종합적인 분석 자료로 구성됩니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료는 엑셀 파일로 제공됩니다.
글로벌 전이성 직장암 시장 보고서는 약 61개의 표, 57개의 그림, 그리고 195페이지 분량으로 구성됩니다.
주요 독자층 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Metastatic Colorectal Cancer Market reached US$ 3.4 billion in 2022 and is expected to reach US$ 4.8 billion by 2030 growing with a CAGR of 4.6% during the forecast period 2023-2030. The metastatic colorectal cancer market is driven by factors such as increasing incidence and prevalence, increased research and development activities, and government initiatives.
Genetic variables, interactions with the tumor microenvironment, and other external factors all play a role in colorectal metastasis. Three types of therapeutic treatments can be used to treat metastatic colorectal cancer (mCRC): systemic chemotherapy, targeted therapy, and immunotherapy.
Market Dynamics
The Increasing FDA Approval for Metastatic Colorectal Cancer Treatment is Driving the Global Metastatic Colorectal Cancer Market Growth
In January 2023, Tucatinib (Tukysa, Seagen Inc.) and trastuzumab received accelerated approval from the Food and Drug Administration for the treatment of RAS wild-type HER2-positive metastatic or unresectable colorectal cancer that has progressed after receiving fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy. An open-label, multicenter experiment called MOUNTAINEER (NCT03043313) examined effectiveness in 84 patients.
Patients had treatment with fluoropyrimidine, oxaliplatin, irinotecan, and an anti-vascular endothelial growth factor (VEGF) monoclonal antibody (mAb) in the past for colorectal cancer that was HER2-positive, RAS wild-type, unresectable or metastatic. Patients who needed to get an anti-programmed cell death protein-1 mAb also had tumors that lacked mismatch repair (dMMR) proteins or had high microsatellite instability (MSI-H).
The Increasing Research Activities are Driving the Global Metastatic Colorectal Cancer Market Growth
In May 2023, Takeda and HUTCHMED (China) Limited reported that the FDA granted priority review of the New Drug Application (NDA) for fruquintinib, a highly potent and selective inhibitor of VEGFR-1, -2, and -3 for the treatment of adult patients with metastatic colorectal cancer (CRC) who have already received treatment.
If authorized, fruquintinib will be the first and only highly selective inhibitor of each of the three VEGF receptors authorized in the United States for metastatic CRC that has already received treatment. The FDA set November 30, 2023, as the Prescription Drug User Fee Act (PDUFA) goal date for this NDA.
Side Effects Associated with Metastatic Colorectal Cancer Therapy are Hampering the Global Metastatic Colorectal Cancer Market Growth
Side effects associated with metastatic colorectal cancer therapy restraining the market growth. Cancer cells are among the fast-dividing cells that chemotherapy treatments target. They can, impact healthy cells, resulting in a number of adverse consequences. Nausea and vomiting, fatigue, hair loss, diarrhea or constipation, bone marrow suppression (lowered blood cell counts), mouth sores, and neuropathy (nerve damage) are typical adverse effects of chemotherapy used to treat mCRC.
Targeted therapies concentrate on specific chemicals implicated in the development of cancer. Targeted therapy for metastatic colorectal cancer (mCRC) frequently causes side effects such as skin reactions (rash, dryness), hypertension (high blood pressure), gastrointestinal problems (diarrhea, nausea), fatigue, abnormalities in liver enzymes, and an increased risk of bleeding or blood clotting.
For more details on this report – Request for Sample
Segment Analysis
The global metastatic colorectal cancer market is segmented based on treatment, drug class, end-user and region.
The Chemotherapy Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period
The chemotherapy segment accounted for the highest market stake accounting for approximately 41.3% of the metastatic colorectal cancer market in 2022. As per the article published in the International Journal of Molecular Sciences in 2023, For mCRC, cytotoxic chemotherapy is still the go-to treatment option. The foundation of combination regimens is made up primarily of fluoropyrimidines.
First-line therapy for metastatic colorectal cancer (mCRC) involves chemotherapy, such as FOLFOX (fluorouracil, leucovorin, and oxaliplatin), FOLFIRI (fluorouracil, leucovorin, and irinotecan), or FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan), either alone or in combination with.
Geographical Penetration
North America Holds a Dominant Position in the Global Metastatic Colorectal Cancer Market
North America is estimated to hold around 39.6% of the total market share in 2023. In September 2022, for patients with metastatic colon cancer for whom traditional therapy is no longer effective, a new phase 2 clinical trial directed by Robert Lentz, MD, a member of the University of Colorado Cancer Centre, may provide hope. In the United States, colorectal cancer is the third most prevalent and third most lethal cancer in both men and women. Furthermore, there are not many viable therapeutic alternatives available once chemotherapy and biological therapy cease to be successful in patients.
The issue is exacerbated by the fact that around 95% of colorectal cancer patients do not respond to immune treatment medications that have already received approval. In order to extend these patients' lives, they must be finding a means to trigger an anti-tumor immune response.
Competitive Landscape
The major global players in the market include Amgen, EMD Serono, Eli Lilly, Genentech, Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Sanofi, Suzhou Zelgen Biopharmaceuticals, and Taiho Oncology among others.
COVID-19 Impact Analysis
Russia-Ukraine Conflict Analysis
The Russia-Ukraine war may affect the metastatic colorectal cancer market due to a lack of facilities being impacted during times of geopolitical instability and economic uncertainty. For cancer treatments to advance, clinical trials are necessary. As a result of the disagreement, new treatments for mCRC may take longer to develop, enrolment of new patients may be delayed, and proper data collecting may be hampered. Infrastructure and healthcare facilities may be destroyed or overburdened during a conflict. This might make it more difficult to give mCRC patients supportive care and specialized cancer therapies.
Artificial Intelligence Analysis:
Artificial intelligence (AI) is increasingly being used in the metastatic colorectal cancer market to improve various aspects of data analysis. To find prospective treatment candidates and molecular targets for metastatic colorectal cancer, AI is utilized in drug discovery to analyze complicated biological and genomic data. By foreseeing potential drug interactions with certain tumor mutations, it can quicken the drug development process.

By Treatment
• Chemotherapy
• Targeted Therapies
• Immunotherapies
• Monotherapy and Combination Therapy
• Others
By Drug class
• Anti-EGFR (Epidermal Growth Factor Receptor) Inhibitors
• Anti-VEGF (Vascular Endothelial Growth Factor) Therapies
• Anti-HER2 (Human Epidermal Growth Factor Receptor 2) Therapies
• Immune Checkpoint Inhibitors
• Others
By End-user
• Hospitals
• Cancer Centers
• Ambulatory Surgical Centers
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In August 2023, Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. reported that the U.S. Food and Drug Administration approved LONSURF (trifluridine/tipiracil) as a single agent or in combination with bevacizumab for the therapy of adult patients with metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.
Why Purchase the Report?
• To visualize the global metastatic colorectal cancer market segmentation based on the treatment, drug class, end-user and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of metastatic colorectal cancer market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global metastatic colorectal cancer market report would provide approximately 61 tables, 57 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Treatment
3.2. Snippet by Drug Class
3.3. Snippet by End-user
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising FDA approval for Metastatic Colorectal Cancer Treatment
4.1.2. Restraints
4.1.2.1. Side effects associated with Metastatic Colorectal Cancer
4.1.3. Opportunity
4.1.3.1. Increasing research activities
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine War Analysis
8. Artificial Intelligence Analysis
9. By Treatment
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
9.1.2. Market Attractiveness Index, By Treatment
9.2. Chemotherapy*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Targeted Therapies
9.4. Immunotherapies
9.5. Others
10. By Drug Class
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.1.2. Market Attractiveness Index, By Drug Class
10.2. Anti-EGFR (Epidermal Growth Factor Receptor) Inhibitors*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Anti-VEGF (Vascular Endothelial Growth Factor) Therapies
10.4. Anti-HER2 (Human Epidermal Growth Factor Receptor 2) Therapies
10.5. Immune Checkpoint Inhibitors
10.6. Others
11. By End-user
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
11.1.2. Market Attractiveness Index, By End-user
11.2. Hospitals*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Cancer Centers
11.4. Ambulatory Surgical Centers
11.5. Others
12. By Region
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.2.6.1. U.S.
12.2.6.2. Canada
12.2.6.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.3.6.1. Germany
12.3.6.2. U.K.
12.3.6.3. France
12.3.6.4. Italy
12.3.6.5. Spain
12.3.6.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.4.6.1. Brazil
12.4.6.2. Argentina
12.4.6.3. Rest of South America
12.5. Asia-Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.5.6.1. China
12.5.6.2. India
12.5.6.3. Japan
12.5.6.4. Australia
12.5.6.5. Rest of Asia-Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
13. Competitive Landscape
13.1. Competitive Scenario
13.2. Product Benchmarking
13.3. Company Share Analysis
13.4. Key Developments and Strategies
14. Company Profiles
14.1. Amgen*
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Financial Overview
14.1.4. Key Developments
14.2. EMD Serono
14.3. Eli Lilly
14.4. Genentech
14.5. Novartis AG
14.6. Pfizer Inc.
14.7. F. Hoffmann-La Roche Ltd
14.8. Sanofi
14.9. Suzhou Zelgen Biopharmaceuticals
14.10. Taiho Oncology
LIST NOT EXHAUSTIVE
15. Appendix
15.1. About Us and Services
15.2. Contact Us

언급된 주요 기업들

Amgen, 4.	Key Developments, EMD Serono, Eli Lilly, Genentech, Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, Sanofi, Suzhou Zelgen Biopharmaceuticals, Taiho Oncology

표 목록 (Tables)

List of Tables

Table 1 Global Metastatic Colorectal Cancer Market Value, By Treatment, 2022, 2026 & 2030 (US$ Billion)

Table 2 Global Metastatic Colorectal Cancer Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Billion)

Table 3 Global Metastatic Colorectal Cancer Market Value, By End-user, 2022, 2026 & 2030 (US$ Billion)

Table 4 Global Metastatic Colorectal Cancer Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 5 Global Metastatic Colorectal Cancer Market Value, By Treatment, 2022, 2026 & 2030 (US$ Billion)

Table 6 Global Metastatic Colorectal Cancer Market Value, By Treatment, 2021-2030 (US$ Billion)

Table 7 Global Metastatic Colorectal Cancer Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Billion)

Table 8 Global Metastatic Colorectal Cancer Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 9 Global Metastatic Colorectal Cancer Market Value, By End-user, 2022, 2026 & 2030 (US$ Billion)

Table 10 Global Metastatic Colorectal Cancer Market Value, By End-user, 2021-2030 (US$ Billion)

Table 11 Global Metastatic Colorectal Cancer Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 12 Global Metastatic Colorectal Cancer Market Value, By Region, 2021-2030 (US$ Billion)

Table 13 North America Metastatic Colorectal Cancer Market Value, By Treatment, 2021-2030 (US$ Billion)

Table 14 North America Metastatic Colorectal Cancer Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 15 North America Metastatic Colorectal Cancer Market Value, By End-user, 2021-2030 (US$ Billion)

Table 16 North America Metastatic Colorectal Cancer Market Value, By Country, 2021-2030 (US$ Billion)

Table 17 South America Metastatic Colorectal Cancer Market Value, By Treatment, 2021-2030 (US$ Billion)

Table 18 South America Metastatic Colorectal Cancer Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 19 South America Metastatic Colorectal Cancer Market Value, By End-user, 2021-2030 (US$ Billion)

Table 20 South America Metastatic Colorectal Cancer Market Value, By Country, 2021-2030 (US$ Billion)

Table 21 Europe Metastatic Colorectal Cancer Market Value, By Treatment, 2021-2030 (US$ Billion)

Table 22 Europe Metastatic Colorectal Cancer Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 23 Europe Metastatic Colorectal Cancer Market Value, By End-user, 2021-2030 (US$ Billion)

Table 24 Europe Metastatic Colorectal Cancer Market Value, By Country, 2021-2030 (US$ Billion)

Table 25 Asia-Pacific Metastatic Colorectal Cancer Market Value, By Treatment, 2021-2030 (US$ Billion)

Table 26 Asia-Pacific Metastatic Colorectal Cancer Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 27 Asia-Pacific Metastatic Colorectal Cancer Market Value, By End-user, 2021-2030 (US$ Billion)

Table 28 Asia-Pacific Metastatic Colorectal Cancer Market Value, By Country, 2021-2030 (US$ Billion)

Table 29 Middle East & Africa Metastatic Colorectal Cancer Market Value, By Treatment, 2021-2030 (US$ Billion)

Table 30 Middle East & Africa Metastatic Colorectal Cancer Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 31 Middle East & Africa Metastatic Colorectal Cancer Market Value, By End-user, 2021-2030 (US$ Billion)

Table 32 Amgen: Overview

Table 33 Amgen: Product Portfolio

Table 34 Amgen: Key Developments

Table 35 EMD Serono: Overview

Table 36 EMD Serono: Product Portfolio

Table 37 EMD Serono: Key Developments

Table 38 Eli Lilly: Overview

Table 39 Eli Lilly: Product Portfolio

Table 40 Eli Lilly: Key Developments

Table 41 Genentech: Overview

Table 42 Genentech: Product Portfolio

Table 43 Genentech: Key Developments

Table 44 Novartis AG: Overview

Table 45 Novartis AG: Product Portfolio

Table 46 Novartis AG: Key Developments

Table 47 Pfizer Inc.: Overview

Table 48 Pfizer Inc.: Product Portfolio

Table 49 Pfizer Inc.: Key Developments

Table 50 F. Hoffmann-La Roche Ltd: Overview

Table 51 F. Hoffmann-La Roche Ltd: Product Portfolio

Table 52 F. Hoffmann-La Roche Ltd: Key Developments

Table 53 Sanofi: Overview

Table 54 Sanofi: Product Portfolio

Table 55 Sanofi: Key Developments

Table 56 Suzhou Zelgen Biopharmaceuticals: Overview

Table 57 Suzhou Zelgen Biopharmaceuticals: Product Portfolio

Table 58 Suzhou Zelgen Biopharmaceuticals: Key Developments

Table 59 Taiho Oncology: Overview

Table 60 Taiho Oncology: Product Portfolio

Table 61 Taiho Oncology: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Metastatic Colorectal Cancer Market Value, 2021-2030 (US$ Billion)

Figure 2 Global Metastatic Colorectal Cancer Market Share, By Treatment, 2022 & 2030 (%)

Figure 3 Global Metastatic Colorectal Cancer Market Share, By Drug Class, 2022 & 2030 (%)

Figure 4 Global Metastatic Colorectal Cancer Market Share, By End-user, 2022 & 2030 (%)

Figure 5 Global Metastatic Colorectal Cancer Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Metastatic Colorectal Cancer Market Y-o-Y Growth, By Treatment, 2022-2030 (%)

Figure 7 Chemotherapy Metastatic Colorectal Cancer Market Value, 2021-2030 (US$ Billion)

Figure 8 Targeted Therapies Metastatic Colorectal Cancer Market Value, 2021-2030 (US$ Billion)

Figure 9 Immunotherapies Metastatic Colorectal Cancer Market Value, 2021-2030 (US$ Billion)

Figure 10 Monotherapy and Combination Therapy Metastatic Colorectal Cancer Market Value, 2021-2030 (US$ Billion)

Figure 11 Others Metastatic Colorectal Cancer Market Value, 2021-2030 (US$ Billion)

Figure 12 Global Metastatic Colorectal Cancer Market Y-o-Y Growth, By Drug Class, 2022-2030 (%)

Figure 13 Anti-EGFR (Epidermal Growth Factor Receptor) Inhibitors Drug Class in Global Metastatic Colorectal Cancer Market Value, 2021-2030 (US$ Billion)

Figure 14 Anti-VEGF (Vascular Endothelial Growth Factor) Therapies Drug Class in Global Metastatic Colorectal Cancer Market Value, 2021-2030 (US$ Billion)

Figure 15 Anti-HER2 (Human Epidermal Growth Factor Receptor 2) Therapies Drug Class in Global Metastatic Colorectal Cancer Market Value, 2021-2030 (US$ Billion)

Figure 16 Immune Checkpoint Inhibitors Drug Class in Global Metastatic Colorectal Cancer Market Value, 2021-2030 (US$ Billion)

Figure 17 Others Drug Class in Global Metastatic Colorectal Cancer Market Value, 2021-2030 (US$ Billion)

Figure 18 Global Metastatic Colorectal Cancer Market Y-o-Y Growth, By End-user, 2022-2030 (%)

Figure 19 Hospitals End-user in Global Metastatic Colorectal Cancer Market Value, 2021-2030 (US$ Billion)

Figure 20 Cancer Centers End-user in Global Metastatic Colorectal Cancer Market Value, 2021-2030 (US$ Billion)

Figure 21 Ambulatory Surgical Centers End-user in Global Metastatic Colorectal Cancer Market Value, 2021-2030 (US$ Billion)

Figure 22 Others End-user in Global Metastatic Colorectal Cancer Market Value, 2021-2030 (US$ Billion)

Figure 23 Global Metastatic Colorectal Cancer Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 24 North America Metastatic Colorectal Cancer Market Value, 2021-2030 (US$ Billion)

Figure 25 Asia-Pacific Metastatic Colorectal Cancer Market Value, 2021-2030 (US$ Billion)

Figure 26 Europe Metastatic Colorectal Cancer Market Value, 2021-2030 (US$ Billion)

Figure 27 South America Metastatic Colorectal Cancer Market Value, 2021-2030 (US$ Billion)

Figure 28 Middle East and Africa Metastatic Colorectal Cancer Market Value, 2021-2030 (US$ Billion)

Figure 29 North America Metastatic Colorectal Cancer Market Value, 2021-2030 (US$ Billion)

Figure 30 North America Metastatic Colorectal Cancer Market Share, By Treatment, 2022 & 2030 (%)

Figure 31 North America Metastatic Colorectal Cancer Market Share, By Drug Class, 2022 & 2030 (%)

Figure 32 North America Metastatic Colorectal Cancer Market Share, By End-user, 2022 & 2030 (%)

Figure 33 North America Metastatic Colorectal Cancer Market Share, By Country, 2022 & 2030 (%)

Figure 34 South America Metastatic Colorectal Cancer Market Value, 2021-2030 (US$ Billion)

Figure 35 South America Metastatic Colorectal Cancer Market Share, By Treatment, 2022 & 2030 (%)

Figure 36 South America Metastatic Colorectal Cancer Market Share, By Drug Class, 2022 & 2030 (%)

Figure 37 South America Metastatic Colorectal Cancer Market Share, By End-user, 2022 & 2030 (%)

Figure 38 South America Metastatic Colorectal Cancer Market Share, By Country, 2022 & 2030 (%)

Figure 39 Europe Metastatic Colorectal Cancer Market Value, 2021-2030 (US$ Billion)

Figure 40 Europe Metastatic Colorectal Cancer Market Share, By Treatment, 2022 & 2030 (%)

Figure 41 Europe Metastatic Colorectal Cancer Market Share, By Drug Class, 2022 & 2030 (%)

Figure 42 Europe Metastatic Colorectal Cancer Market Share, By End-user, 2022 & 2030 (%)

Figure 43 Europe Metastatic Colorectal Cancer Market Share, By Country, 2022 & 2030 (%)

Figure 44 Asia-Pacific Metastatic Colorectal Cancer Market Value, 2021-2030 (US$ Billion)

Figure 45 Asia-Pacific Metastatic Colorectal Cancer Market Share, By Treatment, 2022 & 2030 (%)

Figure 46 Asia-Pacific Metastatic Colorectal Cancer Market Share, By Drug Class, 2022 & 2030 (%)

Figure 47 Asia-Pacific Metastatic Colorectal Cancer Market Share, By End-user, 2022 & 2030 (%)

Figure 48 Asia-Pacific Metastatic Colorectal Cancer Market Share, By Country, 2022 & 2030 (%)

Figure 49 Middle East & Africa Metastatic Colorectal Cancer Market Value, 2021-2030 (US$ Billion)

Figure 50 Middle East & Africa Metastatic Colorectal Cancer Market Share, By Treatment, 2022 & 2030 (%)

Figure 51 Middle East & Africa Metastatic Colorectal Cancer Market Share, By Drug Class, 2022 & 2030 (%)

Figure 52 Middle East & Africa Metastatic Colorectal Cancer Market Share, By End-user, 2022 & 2030 (%)

Figure 53 Amgen: Financials

Figure 54 EMD Serono: Financials

Figure 55 Eli Lilly: Financials

Figure 56 Genentech: Financials

Figure 57 Novartis AG: Financials

Figure 58 Pfizer Inc.: Financials

Figure 59 F. Hoffmann-La Roche Ltd: Financials

Figure 60 Sanofi: Financials

Figure 61 Suzhou Zelgen Biopharmaceuticals: Financials

Figure 62 Taiho Oncology: Financials

세계 전이성 직장암 시장 – 2023-2030

Global Metastatic Colorectal Cancer Market - 2023-2030